Therapy Detail

Therapy Name Cyclophosphamide + MM-398
Therapy Description

MM-398 (PEP02) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
MM-398 PEP02 MM-398 (PEP02) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting